Business Standard

Gland Pharma's growth trajectory to remain elevated in medium term

Margin expansion to support profits, clean regulatory track record to help sustain growth journey

Shanghai Fosun Pharmaceutical
Premium

A strong balance sheet and money raised from the IPO gives the company the flexibility to expand and look at acquisitions to boost its capabilities.

Ram Prasad Sahu Mumbai
The stock of Gland Pharma is up 56 per cent over its initial public offering (IPO) price on expectations that its expertise in the injectables space, a clean regulatory track record, and new launches will help sustain 25 per cent-plus growth rates over the next couple of years. India’s largest pharma IPO was listed last month and has gained 29 per cent since then. 

Among the reasons for investors being bullish about the company is the growth prospects over the near-to-medium term. After posting 21 per cent sales growth over the FY17-20 period, analysts, such as Nikhil Mathur of Ambit Capital,

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Dec 30 2020 | 8:09 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com